产品名称
Anti-PAI-1 (Ab-1) Mouse mAb (2), lyophilized, clone 2, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
2, monoclonal
form
lyophilized
does not contain
preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Immunoblotting (1 µg/mL)
Immunoprecipitation
Immunocytochemistry (s
Neutralization Studies )
isotype
IgG1
shipped in
ambient
storage temp.
2-8°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SERPINE1(5054)
Analysis Note
Positive Control
Conditioned media from dexamethasone-treated (1 µM) HT-1080 cells
Conditioned media from dexamethasone-treated (1 µM) HT-1080 cells
Application
Immunoblotting (1 µg/ml)
Immunoprecipitation (see application references)
Immunocytochemistry (see application references
Neutralization Studies (see application references)
Immunoprecipitation (see application references)
Immunocytochemistry (see application references
Neutralization Studies (see application references)
Disclaimer
Toxicity: Standard Handling (A)
General description
Purified mouse monoclonal antibody (see application references). Recognizes both active and latent forms of the ~50 kDa PAI-1 protein.
Recognizes both active and latent forms of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.
This Anti-PAI-1 (Ab-1) Mouse mAb (2) is validated for use in Immunoblotting, Immunoprecipitation, Immunocytochemistry for the detection of PAI-1 (Ab-1).
Immunogen
Human
partially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
Legal Information
Sold under license of U.S. Patent 5,422,245.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Antibody should be titrated for optimal results in individual systems.
Janicke, F., et al. 1994. Cancer Research.54, 2527.
Lawrence, D. A., et al. 1994. J. Biol. Chem.269, 15223.
Nagayama, M., et al. 1994. Cancer73, 1398.
Petersen, H., et al. 1994. Cancer Res.54, 120.
Keijer, J., et al. 1991. Blood78, 401.
Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol.Vol. 1, 153.
Declerck, P. J. and Collen, D., 1990. Thrombosis Res.Supplement X 3.
Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis.55, 206.
Lawrence, D. A., et al. 1994. J. Biol. Chem.269, 15223.
Nagayama, M., et al. 1994. Cancer73, 1398.
Petersen, H., et al. 1994. Cancer Res.54, 120.
Keijer, J., et al. 1991. Blood78, 401.
Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol.Vol. 1, 153.
Declerck, P. J. and Collen, D., 1990. Thrombosis Res.Supplement X 3.
Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis.55, 206.
Physical form
Lyophilized from a volatile buffer, 100 µg BSA.
Preparation Note
We recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
11 - Combustible Solids
wgk
WGK 1
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持